Under the Paperwork Reduction Act of 1995, no persons are required to re

INFORMATION DISCLOSURE	
STATEMENT BY APPLICANT	
(Not for submission under 37 CFR 1.99)	

Application Number		10598039		
Filing Date		2006-08-16		
First Named Inventor Frede		rik H. IN 'T VELD, ET AL		
Art Unit				
Examiner Name				
Attorney Docket Number		NL050182		

U.S. PATENTS							Remove		
Examiner Initial*	Cite No			Releva		Lines where ges or Relevant			
	1	3623520	A	1971-11-30	NEILD				
	2	4619081	A	1986-10-28	LIPANSKI ET AL				
	3	6325059	B1	2001-12-04	TIEBER				
	4	6187654	B1	2001-02-13	TIEBER				
	5								
If you wisl	n to a	dd additional U.S. Paten	t citatio	n information pl	ease click the Add button.		Add		
			U.S.P	ATENT APPLIC	CATION PUBLICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	20020017888	A1	2002-12-05	YAMAMOTO				
If you wis	to a	dd additional U.S. Publis	hed Ap	plication citation	n information please click the Ad-	d button.			
				FOREIGN PAT	TENT DOCUMENTS		Remove		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Foreign Document

Examiner Cite

Examiner Signature

Initial* No Number3

Application Number		10598039		
Filing Date		2006-08-16		
First Named Inventor	Frederik H. IN 'T VELD, ET AL			
Art Unit				
Examiner Name				
Attorney Docket Number		NI 050182		

Name of Patentee or

Date Considered

Applicant of cited

Document

Pages.Columns.Lines

where Relevant Passages or Relevant

Figures Appear

	1	EP0955119		A1	1999-11-10	skc				
	2	EP0955119		B1	1999-11-10	skc				
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove			
Examiner Initials*	Examiner Cite Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials* No (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Ţ5			
	1 ISR for Publication, Informational Publication Number W02005080059 A1									
If you wis	h to a	dd additional non-paten	t literature docu	ment ci	tation informati	on please click the Add	button Add	_		
			EVANUED CIQUATURE							

Kind Publication

Code4 Date

A

F

Country

Code2 i

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3), 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10598039		
Filing Date		2006-08-16		
First Named Inventor	Frede	rik H. IN 'T VELD, ET AL		
Art Unit				
Examiner Name				
Attorney Docket Number		NI 050182		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s);

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

	on the agriculture.									
	Signature	/Michael E Belk/	Date (YYYY-MM-DD)	2002-11-30						
	Name/Print	Michael F Relk	Registration Number	33357						

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.